1.
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with...
by Bernardino, Jose I
The Lancet (British edition), 2015, Vol.2 (11), p.73
2.
Adverse events of raltegravir and dolutegravir
by Elzi, Luigia
AIDS (London), 2017, Vol.31 (13), p.1853-1858
3.
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up resu...
by Thompson, Jennifer
The Lancet infectious diseases, 2018, Vol.18 (1), p.47-57
4.
Real word outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort
by Santinelli, Letizia
Expert review of anti-infective therapy, 2020, Vol.18 (5), p.485-492
5.
Raltegravir is safely used with long-term viral suppression for HIV-infected patients on hemodialysis: a pharmacokinetic study
by Yanagisawa, Kunio
AIDS (London), 2016, Vol.30 (6), p.970-972
6.
HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M
by Alessandri-Gradt, Elodie
AIDS (London), 2015, Vol.29 (10), p.1271-1273
7.
Relationship between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1 Infected Women on a Raltegravir versus a Boosted Atazanavir Reg...
by Meditz, Amie
AIDS research and human retroviruses, 2015, Vol.31 (ja), p.1015-1022
8.
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING...
by Cahn, Pedro, Dr
The Lancet (British edition), 2013, Vol.382 (9893), p.700-708
9.
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
by Raffi, Francois, Prof
The Lancet (British edition), 2013, Vol.381 (9868), p.735-743
10.
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
by Buzón, Maria J
Nature medicine, 2010, Vol.16 (4), p.460-465
11.
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised control...
by Lennox, Jeffrey L, Prof
The Lancet (British edition), 2009, Vol.374 (9692), p.796-806
12.
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-in...
by Raffi, François, Prof
The Lancet infectious diseases, 2013, Vol.13 (11), p.927-935
13.
Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy
by YUKL, Steven A
AIDS (London), 2010, Vol.24 (16), p.2451-2460
14.
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
by Grinsztejn, Beatriz, MD
The Lancet (British edition), 2007, Vol.369 (9569), p.1261-1269
15.
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
by MARTINEZ, Esteban
AIDS (London), 2010, Vol.24 (11), p.1697-1707
16.
Efficacy of a nucleoside-sparing regimen of darunavir/ ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)
by TAIWO, Babafemi
AIDS (London), 2011, Vol.25 (17), p.2113-2122
17.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 random...
by Raffi, François, Prof
The Lancet (British edition), 2014, Vol.384 (9958), p.1942-1951
18.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two m...
by Eron, Joseph J, Prof
The Lancet (British edition), 2010, Vol.375 (9712), p.396-407
19.
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in a...
by Boyd, M A
The Lancet (British edition), 2013, Vol.381 (9883), p.2091-2099
20.
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection
by PUERTAS, Maria C
AIDS (London), 2014, Vol.28 (3), p.325-334
